Genedrive plc (AIM: GDR), the near-patient molecular diagnostics company, confirms that its Genedrive 96 SARS CoV-2 Kit continues to detect all known variants of COVID-19, including the newest variants released
Genedrive notifies FDA of its intent to distribute to SARS-CoV-2 PCR test in the USA
In the interim results for the six months ended 30 September 2020, the board of Braveheart (the “Board”) announced that it had declared the payment of a special interim dividend
Hepatitis C virus testing kit reveals 100% sensitivity and specificity when compared to Abbott Realtime HCV test
Braveheart announces that on 18 November 2020, it sold a total of 112,592,405 ordinary shares in Remote Monitored System plc (“RMS”).
Braveheart announces that on 16 and 17 November 2020, it sold a total of 287,400,000 ordinary shares in Remote Monitored System plc (“RMS”) at a weighted average price of approximately
Braveheart announces that on 6 November 2020 it exercised a total of 10 million options over ordinary shares in Remote Monitored Systems plc (“RMS”) at an exercise price of 0.5p
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it will release its financial results for the year ended 30 June 2020 on Tuesday 17 November 2020.
Braveheart Investment Group (AIM: BRH) provides an update on progress with the Pharm2Farm Limited (“P2F”) anti-viral surgical mask project.
Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it has completed the assay design for the Company’s Point-of-Care (“POC”) solution for COVID-19 testing and is now generating
Braveheart Investment Group (AIM: BRH), is pleased to provide an update concerning progress with proof of concept for a COVID-19 test that Paraytec Limited is conducting with the University of
